Patricio Bellver-Serra

Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal: Journal for immunotherapy of cancer

Published: March 31, 2026

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 25, 2024

Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.

Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.

Journal: Nature medicine

Published: June 20, 2023

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 19, 2022

Tumour infiltrating B cells discriminate checkpoint blockade-induced responses.

Tumour infiltrating B cells discriminate checkpoint blockade-induced responses.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 06, 2022

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 20, 2022

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 10, 2022

Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.

Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 27, 2021

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.

Journal: The Lancet. Oncology

Published: July 12, 2021

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.

Journal: Nature medicine

Published: March 24, 2021

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

Journal: The Lancet. Oncology

Published: November 29, 2020

The role of nivolumab in melanoma.

The role of nivolumab in melanoma.

Journal: Future oncology (London, England)

Published: January 13, 2018

Showing 1-12 of 13

Last Updated: 09/26/2026